| Submission declined on 9 September 2024 by Iwaqarhashmi (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Overview
editThe Institute of Oncology Research (IOR, in Italian Istituto Oncologico di Ricerca), is a not-for-profit research institute located in Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI).
Established in 2003, the IOR research spam from basic research to translational and clinical research on various aspects of cancer biology, diagnosis and therapy. The IOR has also an intense cooperation with the clinical research activities at the Oncology Institute of Southern Switzerland (IOSI).
History
editThe IOR was founded in 2003 under the name of “Laboratory of Experimental Oncology “as a research division of the Oncology Institute of Southern Switzerland (IOSI).
In September 2011, the Institute became independent and is managed administratively by the Foundation for the Institute of Oncology Research (President, Prof. Franco Cavalli).
As of January 2017, following a University Council decision in 2015, the IOR became an academic institute affiliated to the Faculty of Biomedical Sciences of the Università della Svizzera italiana (USI).
From July 2021, the IOR, together with the Institute for Research in Biomedicine (IRB), is member of the Bellinzona Institutes of Science (Bios+), a non-profit association aiming to promote, support and coordinate the scientific research and teaching activities of its members.
Governance
editThe Foundation for the Institute of Oncology Research, an independent Foundation, is the governing body of the IOR.
The IOR Foundation was founded in 1999 under the name of “Foundation for the Research and Treatment of Lymphoma in Ticino”. The Foundation took over the International Conference on Malignant Lymphoma of Lugano (ICML), organized since 1981, played an important role in financing the development of the International Extranodal Lymphoma Study Group (IELSG) and in supporting the creation of a lymphoma database of the Oncology Institute of Southern Switzerland (IOSI).
In 2011, the Foundation has taken over the management of the research laboratories of the Oncology Institute of Southern Switzerland (IOSI)., giving birth to the Institute of Oncology Research (IOR).
In 2018, since the management of the IOR has become the principal activity of the Foundation, the Foundation changed its name into "Foundation for the Institute of Oncology Research”.
Research
editWith eight active research groups, the IOR hosts researchers from all over the world performing basic and translational research in oncology, with special focus on cancer biology, genomics, molecular oncology and experimental therapeutics.
With approximately 120 researchers (data updated on 2024), the IOR operates two main research programs: the "Tumor Biology and Experimental Therapeutics Research Program”, focusing on solid tumors, and the "Lymphoma and Genomics Research Program", addressing hematological neoplasias and lymphomas.
Researchers at the IOR employ an interdisciplinary approach, integrating biological, genomics, and molecular methods with preclinical and translational studies.
The Institute emphasizes collaboration and interaction among teams and programs to achieve common goals, such as understanding cancer mechanisms and developing new diagnostic and therapeutic strategies.
Publications
editSince 2003, more than 650 articles (data updated in 2024) were published by the IOR in various scientific journals, notably in leading academic journals as Cell, Nature and Science.
Education
editCommitted to education and training, the IOR collaborates with international universities and research centers. It contributes to the educational programs of the Faculty of Biomedical Sciences at the Università della Svizzera italiana (USI) and the doctoral school, offering a PhD Program in Cancer Biology and Oncology.
The Institute also actively organizes academic and training courses and most IOR Group Leaders have professorial or lecturer appointments at USI. Some of them have also appointments at other universities and at the ETH Zürich.
Building and facilities
editIn 2021, the IOR moved to a new headquarters in Bellinzona (owned by the IRB Foundation), with modern laboratories and updated core facilities. In addition to the IRB and the IOR, the new building also hosts the Laboratories of Translational Research of the Ente Ospedaliero Cantonale (LTR-EOC).
Funding
editAs academic and non-profit organizations, the IOR and the IOR Foundation receive institutional funding from the Swiss Confederation, the Canton of Ticino, and the City of Bellinzona.
Researchers secure competitive funding from national and international agencies, including the Swiss National Science Foundation, Innosuisse, the Swiss Cancer League, the Swiss Cancer Research Foundation, the Fondazione Ticinese Ricerca Cancro, the European Community, and private foundations.
Private donations are also vital for sustaining research support, training programs, and enhancing technology platforms.